The global flow cytometry market size was valued at USD 4,255.8 million in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 7.17% from 2023 to 2030. The growing prevalence of cancer, immunodeficiency disorders, and infectious diseases is driving industry growth. Moreover, rising R&D investments in biotechnology, life science, and biopharmaceutical research activities have also led to high demand for flow cytometry instruments. In addition, technological advancements in the technique are introducing new and improved analytical tools, which include the development of microfluidic flow cytometry for Point-of-Care (POC) testing.
The COVID-19 pandemic led to an increase in the applications of flow cytometry. The technique offers a promising alternative for COVID-19 testing as it can overcome the limitations of current PCR or antibody-based testing options due to its higher accuracy and throughput capacity. Hence, the adoption of flow cytometry-based techniques for COVID-19 diagnostics and disease surveillance has contributed to the industry's growth. In addition, the pandemic has also spurred innovations in the flow cytometry space, as evidenced by the launch of new products in this domain. For instance, in July 2021, Eurofins Viracor, Inc. launched its Coronavirus SARS-CoV-2 inSIGHT T Cell Immunity testing platform.
The test utilizes flow cytometry to deliver vital information regarding a patient’s response to COVID-19 antigens and aids in ascertaining effective treatment decisions. The launch of such innovations is anticipated to fuel industry growth in the near future. The rising prevalence of infectious diseases globally is another factor driving the adoption of flow cytometry techniques. AIDS and tuberculosis lead to over 4.5 million deaths annually, and efficient immunophenotyping & cell isolation alternatives are essential for the mitigation of these diseases. The technique can offer a promising option for immunophenotyping, and pathogenic microbes can be easily detected from environmental samples using this technique.
As the infectious disease burden is substantially high in low- and lower-middle-income countries, a persistent rise in mortality due to emerging and re-emerging infectious diseases is anticipated to increase the demand for highly efficient testing options, such as flow cytometry. Moreover, increasing investments in major biotechnology & biopharmaceutical companies are significantly boosting industry growth. For instance, in 2020, GlaxoSmithKline announced an investment of over USD 250 million in Vir Biotechnology, a clinical-stage immunology company, for supporting its antibody drug development program for COVID-19.
In addition, in January 2021, Pfizer Inc. invested USD 120 million as a part of the Pfizer Breakthrough Growth Initiative (PBGI) in biotechnology innovation. Such investments and funding have resulted in a robust R&D infrastructure in biotechnology, biopharmaceutical, clinical, and life sciences research. This is expected to further strengthen R&D for cell analysis in the field of new drug discovery and development activities with flow cytometry techniques. Furthermore, technological advancements in the latest flow cytometry instrumentation are resulting in enhanced accuracy, efficiency, and cost-effectiveness of these systems, which is expected to present new growth opportunities for the industry.
Digital signal processing has revolutionized the field of flow cytometry. Novel product offerings are being launched to integrate digital and imaging technologies into regular flow cytometry procedures. For instance, in July 2021, Thermo Fisher Scientific, Inc. launched its Invitrogen Attune CytPix Flow Cytometer, which can combine acoustic focusing technology with an imaging camera. This enables the collection of flow cytometry data as well as high-resolution images at the same time. Such advancements can add significant value to the data collected in the technique and can positively impact industry growth.
In addition, the rising demand for PoC diagnostics for HIV and other sexually transmitted diseases is one of the factors propelling the market demand. Rising awareness among healthcare professionals regarding the accuracy & sensitivity of the technique is contributing to industry growth. Some of the major factors responsible for the high growth of flow cytometry techniques in point-of-care healthcare facilities are supportive government initiatives and the availability of advanced instruments capable of multiplexing applications. In addition, clinics and other healthcare establishments are focusing on providing effective & rapid diagnostic results by switching to point-of-care tests, which is expected to drive market growth.
The instrument segment dominated the market a share of 35.47% in 2022 with owing to higher penetration coupled with technological advancements. In January 2022, Sony Biotechnology, Inc. introduced its CGX10, a new closed-cell isolation system for use in GMP-compliant cell sorting applications. The initiative was expected to open new growth opportunities for the company. Such advancements in technology result in cost-effectiveness, enhanced accuracy, & portability and are likely to create future growth opportunities.
Small-sized high-throughput cytometers are likely to gain acceptance in the coming years. This is due to allied advantages, such as user-friendliness and cost-effectiveness. Software segment is expected to witness significant growth with a CAGR of 8.66% during the forecast years. The software in flow cytometry is used to control & acquire data generated by cytometers, analyze the information, and provide statistical analysis of the outcomes. For research purposes, the software is used for cell acquisition & data analysis, while in clinical diagnosis, it is used for disease diagnosis by analyzing patients’ samples.
Such wide applications are projected to boost the industry in near future. Moreover, new product developments by key companies are among other significant factors driving the segment growth. For instance, in September 2022, BD announced the launch of a BD software solution specifically designed for flow cytometry workflow. This software enables higher-quality experiments with faster time to insight for scientists working in various disciplines such as oncology, virology immunology, and infectious disease monitoring.
Cell-based flow cytometry held the largest revenue share of over 76.43% in 2022 and accounted for the maximum share of more than 77.25% of the overall revenue. Increasing awareness about the benefits associated with cell-based assays and rising demand for early diagnosis are factors contributing to its dominance. Furthermore, technological advancements in cell-based assays, such as innovation in software, instruments, algorithms, affinity reagents, and labels, are expected to drive the adoption in the coming years. The bead-based assay segment is estimated to grow at a significant CAGR of more than during the forecast period.
Bead-based flow cytometry is used to measure various intracellular soluble proteins, including growth factors, cytokines, chemokines, and phosphorylated cell signaling proteins. High-throughput flow cytometry technique is considered an optimal tool for conducting multiplex bead-based assays. Multiplex bead-based technique has high growth potential in the field of research, diagnosis, and treatment of infectious diseases. The need for these assays is expected to show lucrative growth in the coming years owing to advancements in monoclonal antibody production and molecular engineering and the accompanying advantages, such as cost-efficiency, short turnaround time, and micro-sampling capabilities.
Clinical segment accounted for a major share of 45.44% in 2022. This high share can be attributed to increasing research & development activities pertaining to cancer and infectious diseases, including COVID-19. Furthermore, rising R&D investments in the biotechnology and pharmaceutical industry are likely to create a conducive environment for market growth. In addition, Furthermore, unceasing growth strategies by key players in the industry and the launch of novel flow cytometry solutions for clinical applications are also anticipated to significantly support segment growth. For instance, in March 2022, Beckman Coulter launched CellMek SPS, which is a powerful solution for data management and manual sample preparation bottlenecks in clinical flow cytometry. The industrial segment is expected to be the fastest-growing segment with a CAGR of 7.76% due to the increasing applications of flow cytometry in cell culture.
This is due to the increasing applications of flow cytometry in cell culture. The technique finds applications in the pharmaceutical industry, such as drug development process including, target identification, drug characteristics & compound screening, non-clinical safety and toxicity evaluation, and clinical research. Flow cytometry offers a high throughput and rapidity for large-scale drug development and testing detects multiple parameters on the cell surface, coupled with data analysis generates complex and sufficient data by excluding false positives in single-parameter tests. The associated advantages of using flow cytometry in large-scale bioprocessing operations for drug development are expected to fuel market growth over the forecast period.
The academic institutes segment captured the highest revenue share of 31.42% in 2022. The technique is used in cell biology & molecular diagnostic studies to measure cell parameters such as the physical properties of cells and recognition of biomarkers through specific antibodies, cell type, cell lineage, and maturation stage. This technology has applications in several educational fields, including molecular biology, immunology, pathology, plant biology, and marine biology. With rising R&D activities, the segment is expected to exhibit significant growth during the forecast period.
The clinical testing labs segment is anticipated to be the fastest-growing segment with a CAGR of 8.19% due to the growing need for cost-effective diagnosis of target diseases such as cancer. It is a widely used tool in the diagnosis and treatment of cancers and immunodeficiency diseases. The rising prevalence of cancer and chronic diseases has resulted in a high demand for diagnostic tests, which is expected to drive the demand for the technique in clinical testing laboratories over the forecast period.
North America dominated the overall market with a share of 41.01% in 2022. This dominance is due to the high implementation of scientifically advanced flow cytometry solutions, high healthcare expenditure, and well-established healthcare infrastructure in the U.S. In addition, widespread research activities by research universities and the presence of established pharmaceutical companies have generated a huge demand for flow cytometry workflow for research needs. In addition, the high prevalence of infectious and chronic diseases, including the outbreak of COVID-19, has led to an increase in the demand for the technique for research and diagnosis purposes.
Asia Pacific is anticipated to witness a significant CAGR of 8.09% during the forecast period as a result of the growing pharmaceutical and biotechnology industries in emerging economies, such as China and India. The industry is driven by the growing incidence of chronic diseases and the increasing use of cytometry devices in various applications in the region. Moreover, ongoing innovations in the fields of cancer & infectious illnesses, such as COVID-19, are expected to drive the regional market. In addition, extensive research activities by regional players for the improvement or development of innovative flow cytometry solutions are expected to support market growth in the region over the projected period.
Key players in the industry are implementing various strategies including new product launches investments, strategic collaborations, geographical expansions, and partnerships through mergers & acquisitions to expand their market presence. For instance, in March 2022, Beckman Coulter (Danaher Corp.) launched CellMek SPS, which is a powerful solution for data management and manual sample preparation bottlenecks in clinical flow cytometry. In addition, in October 2021, BD Life Sciences in partnership with Vellore, Christian Medical College launched a Center of Excellence in flow cytometry for medical research in India to enhance its market presence. Some of the prominent key players in the global flow cytometry market include:
Becton, Dickinson, and Company (BD)
Agilent Technologies, Inc.
Apogee Flow Systems Ltd.
Bio-Rad Laboratories, Inc.
Thermo Fisher Scientific, Inc.
Sony Biotechnology, Inc.
Market size value in 2023
USD 4,637.5 million
Revenue forecast in 2030
USD 7,531.2 million
CAGR of 7.17% from 2023 to 2030
Base year for estimation
2019 - 2021
2023 - 2030
Revenue in USD million/billion and CAGR from 2023 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Product, technology, application, end-use, region
North America; Europe; Asia Pacific; Latin America; Middle East & Africa
U.S.; Canada; Germany; U.K.; France; Italy; Spain; Russia; China; Japan; India; South Korea; Australia; Singapore; Brazil; Mexico; Argentina; UAE; South Africa; Saudi Arabia
Key companies profiled
Danaher Corp.; Becton, Dickinson and Company (BD);Sysmex Corp.; Agilent Technologies, Inc.; Apogee Flow Systems Ltd.; Bio-Rad Laboratories, Inc.; Thermo Fisher Scientific, Inc.; Stratedigm, Inc.; DiaSorin S.p.A.; Miltenyi Biotec; Sony Biotechnology, Inc.
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs.Explore purchase options
This report forecasts revenue growth and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global flow cytometry market report on the basis of product, technology, application, end-use, and region:
Product Outlook (Revenue, USD Million, 2018 - 2030)
Reagents & Consumables
Technology Outlook (Revenue, USD Million, 2018 - 2030)
Application Outlook (Revenue, USD Million, 2018 - 2030)
In Vitro Toxicity
Cell Cycle Analysis
End-use Outlook (Revenue, USD Million, 2018 - 2030)
Clinical Testing Labs
Regional Outlook (Revenue, USD Million, 2018 - 2030)
Middle East & Africa
b. The global flow cytometry market size was estimated at USD 4.26 billion in 2022 and is expected to reach USD 4.64 billion in 2023.
b. The global flow cytometry market is expected to grow at a compound annual growth rate of 7.17% from 2023 to 2030 to reach USD 7.53 billion by 2030.
b. North America dominated the flow cytometry market with a share of 41.01% in 2022. This is attributable to an established healthcare sector and supportive government policies for developing advanced technologies for molecular diagnostics in the region.
b. Some key players operating in the flow cytometry market include Danaher Corporation; Becton, Dickinson and Company; DiaSorin S.p.A.; Agilent Technologies, Inc.; Bio-Rad Laboratories, Inc.; Miltenyi Biotec; Sysmex Corporation; Stratedigm, Inc.; Apogee Flow Systems Ltd.; Sony Biotechnology, Inc.; and Thermo Fisher Scientific, Inc.
b. Key factors driving the flow cytometry market growth include the rising R&D investments in the biotechnology sector and technological advancements in the field of flow cytometry for introducing new and improved analytical tools, such as microfluidic flow cytometry, for point-of-care testing.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."